Androgen receptor variation affects prostate cancer progression and drug resistance

Pharmacological Research

Volumn 114, Issue , 2016, Pages 152-162

  McCrea, Edel ^a   Sissung, Tristan M ^a   Price, Douglas K ^a   Chau, Cindy H ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; AR V7; Mutation; Pharmacology; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; APALUTAMIDE; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GALETERONE; GELDANAMYCIN; KETOCONAZOLE; NATURAL PRODUCT; NICLOSAMIDE; NILUTAMIDE; NIPHATENONE; ODM 201; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN;

CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ANIMAL; DISEASE EXACERBATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC VARIATION; GENETICS; MALE; METABOLISM; MUTATION; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MUTATION; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84994314198     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.10.001     Document Type: Review

References (93)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA. Cancer J. Clin. 66:1 (2016), 7–30.
2. [2] Shafi, A.A., Putluri, V., Arnold, J.M., Tsouko, E., Maity, S., Roberts, J.M., Coarfa, C., Frigo, D.E., Putluri, N., Sreekumar, A., Weigel, N.L., Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6:31 (2015), 31997–32012.
3. [3] Azad, A.A., Zoubeidi, A., Gleave, M.E., Chi, K.N., Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat. Rev. Urol. 12:1 (2015), 26–36.
4. [4] Srinivas-Shankar, U., Wu, F.C., Drug insight: testosterone preparations. Nat. Clin. Pract. Urol. 3:12 (2006), 653–665.
5. [5] Zhou, J., Geng, G., Shi, Q., Sauriol, F., Wu, J.H., Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J. Med. Chem. 52:17 (2009), 5546–5550.
6. [6] Lonergan, P.E., Tindall, D.J., Androgen receptor signaling in prostate cancer development and progression. J. Carcinog., 10, 2011, 20.
7. [7] Clinckemalie, L., Vanderschueren, D., Boonen, S., Claessens, F., The hinge region in androgen receptor control. Mol. Cell. Endocrinol. 358:1 (2012), 1–8.
8. [8] Thadani-Mulero, M., Portella, L., Sun, S., Sung, M., Matov, A., Vessella, R.L., Corey, E., Nanus, D.M., Plymate, S.R., Giannakakou, P., Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 74:8 (2014), 2270–2282.
9. [9] Wagstaff, K.M., Jans, D.A., Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 10:9 (2009), 1188–1198.
10. [10] Gordon, V., Bhadel, S., Wunderlich, W., Zhang, J., Ficarro, S.B., Mollah, S.A., Shabanowitz, J., Hunt, D.F., Xenarios, I., Hahn, W.C., Conaway, M., Carey, M.F., Gioeli, D., CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol. Endocrinol. 24:12 (2010), 2267–2280.
11. [11] Dehm, S.M., Tindall, D.J., Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 18:5 (2011), R183–196.
12. [12] Sissung, T.M., Reece, K.M., Spencer, S., Figg, W.D., Contribution of the OATP1 B subfamily to cancer biology and treatment. Clin. Pharmacol. Ther. 92:5 (2012), 658–660.
13. [13] Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L., Zhao, Y., DiConcini, D., Puxeddu, E., Esen, A., Eastham, J., Weigel, N.L., Lamb, D.J., Androgen receptor mutations in prostate cancer. Cancer Res. 60:4 (2000), 944–949.
14. [14] Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N., Balk, S.P., Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:21 (1995), 1393–1398.
15. [15] Liu, H., An, X., Li, S., Wang, Y., Li, J., Liu, H., Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations. Mol. Biosyst. 11:12 (2015), 3347–3354.
16. [16] Brooke, G.N., Bevan, C.L., The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 10:1 (2009), 18–25.
17. [17] Gottlieb, B., Beitel, L.K., Wu, J.H., Trifiro, M., The androgen receptor gene mutations database (ARDB). Hum. Mutat. 23:6 (2004), 527–533 2004 update.
18. [18] Azad, A.A., Volik, S.V., Wyatt, A.W., Haegert, A., Le Bihan, S., Bell, R.H., Anderson, S.A., McConeghy, B., Shukin, R., Bazov, J., Youngren, J., Paris, P., Thomas, G., Small, E.J., Wang, Y., Gleave, M.E., Collins, C.C., Chi, K.N., Androgen receptor gene aberrations in circulating cell-Free DNA: biomarkers of therapeutic resistance in castration-Resistant prostate cancer. Clin. Cancer Res. 21:10 (2015), 2315–2324.
19. [19] Duff, J., McEwan, I.J., Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol. Endocrinol. 19:12 (2005), 2943–2954.
20. [20] Brooke, G.N., Parker, M.G., Bevan, C.L., Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27:21 (2008), 2941–2950.
21. [21] Korpal, M., Korn, J.M., Gao, X., Rakiec, D.P., Ruddy, D.A., Doshi, S., Yuan, J., Kovats, S.G., Kim, S., Cooke, V.G., Monahan, J.E., Stegmeier, F., Roberts, T.M., Sellers, W.R., Zhou, W., Zhu, P., An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3:9 (2013), 1030–1043.
22. [22] Mahmoud, A.M., Zhu, T., Parray, A., Siddique, H.R., Yang, W., Saleem, M., Bosland, M.C., Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One, 8(10), 2013, e78479.
23. [23] Veldscholte, J., Berrevoets, C.A., Ris-Stalpers, C., Kuiper, G.G., Jenster, G., Trapman, J., Brinkmann, A.O., Mulder, E., The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41:3-8 (1992), 665–669.
24. [24] Steketee, K., Timmerman, L., Ziel-van der Made, A.C., Doesburg, P., Brinkmann, A.O., Trapman, J., Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int. J. Cancer 100:3 (2002), 309–317.
25. [25] Hu, R., Dunn, T.A., Wei, S., Isharwal, S., Veltri, R.W., Humphreys, E., Han, M., Partin, A.W., Vessella, R.L., Isaacs, W.B., Bova, G.S., Luo, J., Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69:1 (2009), 16–22.
26. [26] Hornberg, E., Ylitalo, E.B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., Wikstrom, P., Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One, 6(4), 2011, e19059.
27. [27] Dehm, S.M., Schmidt, L.J., Heemers, H.V., Vessella, R.L., Tindall, D.J., Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68:13 (2008), 5469–5477.
28. [28] Nadiminty, N., Tummala, R., Liu, C., Lou, W., Evans, C.P., Gao, A.C., NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol. Cancer Ther. 14:8 (2015), 1884–1895.
29. [29] Blanchette, M., Green, R.E., MacArthur, S., Brooks, A.N., Brenner, S.E., Eisen, M.B., Rio, D.C., Genome-wide analysis of alternative pre-mRNA splicing and RNA-binding specificities of the Drosophila hnRNP A/B family members. Mol. Cell 33:4 (2009), 438–449.
30. [30] Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.S., Bakacs, A., Coppola, L., Karni, R., Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res. 71:13 (2011), 4464–4472.
31. [31] Watson, P.A., Chen, Y.F., Balbas, M.D., Wongvipat, J., Socci, N.D., Viale, A., Kim, K., Sawyers, C.L., Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 107:39 (2010), 16759–16765.
32. [32] Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S.S., Lee, P., Sartor, O., Flemington, E.K., Zhang, H., Hu, C.D., Dong, Y., Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res. 75:17 (2015), 3663–3671.
33. [33] Yamaoka, M., Hara, T., Kusaka, M., Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin. Cancer Res. 16:17 (2010), 4319–4324.
34. [34] Yu, Z., Chen, S., Sowalsky, A.G., Voznesensky, O.S., Mostaghel, E.A., Nelson, P.S., Cai, C., Balk, S.P., Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin. Cancer Res. 20:6 (2014), 1590–1600.
35. [35] Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D.E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C.G., Kung, H.J., Brodie, A.M., Edwards, J., Qiu, Y., A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69:6 (2009), 2305–2313.
36. [36] Taplin, M.E., Bubley, G.J., Ko, Y.J., Small, E.J., Upton, M., Rajeshkumar, B., Balk, S.P., Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59:11 (1999), 2511–2515.
37. [37] Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.S., Pezaro, C., Omlin, A., Rodrigues, D.N., Flohr, P., Tunariu, N., SdB, J., Demichelis, F., Attard, G., Tumor clone dynamics in lethal prostate cancer. Sci. Trans. Med., 6(254), 2014, 254ra125.
38. [38] Beltran, H., Yelensky, R., Frampton, G.M., Park, K., Downing, S.R., MacDonald, T.Y., Jarosz, M., Lipson, D., Tagawa, S.T., Nanus, D.M., Stephens, P.J., Mosquera, J.M., Cronin, M.T., Rubin, M.A., Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63:5 (2013), 920–926.
39. [39] Bohl, C.E., Gao, W., Miller, D.D., Bell, C.E., Dalton, J.T., Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 102:17 (2005), 6201–6206.
40. [40] O'Neill, D., Jones, D., Wade, M., Grey, J., Nakjang, S., Guo, W., Cork, D., Davies, B.R., Wedge, S.R., Robson, C.N., Gaughan, L., Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. Oncotarget 6:28 (2015), 26029–26040.
41. [41] Urushibara, M., Ishioka, J., Hyochi, N., Kihara, K., Hara, S., Singh, P., Isaacs, J.T., Kageyama, Y., Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 67:8 (2007), 799–807.
42. [42] Fenton, M.A., Shuster, T.D., Fertig, A.M., Taplin, M.E., Kolvenbag, G., Bubley, G.J., Balk, S.P., Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 3:8 (1997), 1383–1388.
43. [43] Marhefka, C.A., Moore, B.M. 2nd, Bishop, T.C., Kirkovsky, L., Mukherjee, A., Dalton, J.T., Miller, D.D., Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44:11 (2001), 1729–1740.
44. [44] Scher, H.I., Beer, T.M., Higano, C.S., Anand, A., Taplin, M.E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E.Y., Alumkal, J., Hung, D., Hirmand, M., Seely, L., Morris, M.J., Danila, D.C., Humm, J., Larson, S., Fleisher, M., Sawyers, C.L., Prostate cancer foundation/department of defense prostate cancer clinical trials C: antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:9724 (2010), 1437–1446.
45. [45] Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V., Wongvipat, J., Smith-Jones, P.M., Yoo, D., Kwon, A., Wasielewska, T., Welsbie, D., Chen, C.D., Higano, C.S., Beer, T.M., Hung, D.T., Scher, H.I., Jung, M.E., Sawyers, C.L., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:5928 (2009), 787–790.
46. [46] Attard, G., Reid, A.H., A'Hern, R., Parker, C., Oommen, N.B., Folkerd, E., Messiou, C., Molife, L.R., Maier, G., Thompson, E., Olmos, D., Sinha, R., Lee, G., Dowsett, M., Kaye, S.B., Dearnaley, D., Kheoh, T., Molina, A., de Bono, J.S., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27:23 (2009), 3742–3748.
47. [47] Nadal, R., Tsai, H.L., Sinibaldi, V.J., Paller, C.J., Antonarakis, E.S., Denmeade, S.R., Carducci, M.A., Eisenberger, M.A., Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate 76:5 (2015), 512–520.
48. [48] Crona, D.J., Milowsky, M.I., Whang, Y.E., Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin. Pharmacol. Ther. 98:6 (2015), 582–589.
49. [49] Li, Y., Chan, S.C., Brand, L.J., Hwang, T.H., Silverstein, K.A., Dehm, S.M., Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73:2 (2013), 483–489.
50. [50] Antonarakis, E.S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J.C., Chen, Y., Mohammad, T.A., Chen, Y., Fedor, H.L., Lotan, T.L., Zheng, Q., De Marzo, A.M., Isaacs, J.T., Isaacs, W.B., Nadal, R., Paller, C.J., Denmeade, S.R., Carducci, M.A., Eisenberger, M.A., Luo, J., AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371:11 (2014), 1028–1038.
51. [51] Hu, R., Lu, C., Mostaghel, E.A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W.B., Nelson, P.S., Bluemn, E., Plymate, S.R., Luo, J., Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72:14 (2012), 3457–3462.
52. [52] Joseph, J.D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E.C., Chen, I., Darimont, B., Hager, J.H., A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 3:9 (2013), 1020–1029.
53. [53] Balbas, M.D., Evans, M.J., Hosfield, D.J., Wongvipat, J., Arora, V.K., Watson, P.A., Chen, Y., Greene, G.L., Shen, Y., Sawyers, C.L., Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife, 2, 2013, e00499.
54. [54] O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., Jarman, M., Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90:12 (2004), 2317–2325.
55. [55] Toren, P.J., Kim, S., Pham, S., Mangalji, A., Adomat, H., Guns, E.S., Zoubeidi, A., Moore, W., Gleave, M.E., Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol. Cancer Ther. 14:1 (2015), 59–69.
56. [56] Darshan, M.S., Loftus, M.S., Thadani-Mulero, M., Levy, B.P., Escuin, D., Zhou, X.K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S.T., Bander, N.H., Nanus, D.M., Giannakakou, P., Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71:18 (2011), 6019–6029.
57. [57] Zhu, M.L., Horbinski, C.M., Garzotto, M., Qian, D.Z., Beer, T.M., Kyprianou, N., Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70:20 (2010), 7992–8002.
58. [58] Kraus, L.A., Samuel, S.K., Schmid, S.M., Dykes, D.J., Waud, W.R., Bissery, M.C., The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest. New Drugs 21:3 (2003), 259–268.
59. [59] Maughan, B.L., Antonarakis, E.S., Clinical relevance of androgen receptor splice variants in castration-resistant prostate cancer. Curr. Treat. Options Oncol., 16(12), 2015, 57.
60. [60] Antonarakis, E.S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C.J., Denmeade, S.R., Carducci, M.A., Eisenberger, M.A., Luo, J., Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 1:5 (2015), 582–591.
61. [61] Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A.H., Mulick Cassidy, A., Olmos, D., Attard, G., de Bono, J., Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann. Oncol. 23:11 (2012), 2943–2947.
62. [62] Pandini, G., Mineo, R., Frasca, F., Roberts, C.T. Jr., Marcelli, M., Vigneri, R., Belfiore, A., Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 65:5 (2005), 1849–1857.
63. [63] Culig, Z., Hobisch, A., Cronauer, M.V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., Klocker, H., Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:20 (1994), 5474–5478.
64. [64] Zengerling, F., Azoitei, A., Herweg, A., Jentzmik, F., Cronauer, M.V., Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7. World J. Urol. 34:5 (2015), 633–639.
65. [65] Kato, H., Sekine, Y., Furuya, Y., Miyazawa, Y., Koike, H., Suzuki, K., Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem. Biophys. Res. Commun. 461:1 (2015), 115–121.
66. [66] Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F., Pellegrini, F., Nicolucci, A., Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One, 8(8), 2013, e71583.
67. [67] Chen, Y., Sawyers, C.L., Scher, H.I., Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 8:4 (2008), 440–448.
68. [68] Shafi, A.A., Yen, A.E., Weigel, N.L., Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol. Ther. 140:3 (2013), 223–238.
69. [69] He, S., Zhang, C., Shafi, A.A., Sequeira, M., Acquaviva, J., Friedland, J.C., Sang, J., Smith, D.L., Weigel, N.L., Wada, Y., Proia, D.A., Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int. J. Oncol. 42:1 (2013), 35–43.
70. [70] Fernandez, E.V., Reece, K.M., Ley, A.M., Troutman, S.M., Sissung, T.M., Price, D.K., Chau, C.H., Figg, W.D., Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells. Mol. Pharmacol. 87:6 (2015), 1006–1012.
71. [71] Qu, Y., Dai, B., Ye, D., Kong, Y., Chang, K., Jia, Z., Yang, X., Zhang, H., Zhu, Y., Shi, G., Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci. Rep., 5, 2015, 7654.
72. [72] Liu, C., Lou, W., Zhu, Y., Nadiminty, N., Schwartz, C.T., Evans, C.P., Gao, A.C., Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res. 20:12 (2014), 3198–3210.
73. [73] Liu, C., Lou, W., Armstrong, C., Zhu, Y., Evans, C.P., Gao, A.C., Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate 75:13 (2015), 1341–1353.
74. [74] Lin, T.H., Izumi, K., Lee, S.O., Lin, W.J., Yeh, S., Chang, C., Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (enzalutamide) or casodex (bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell. Death. Dis., 4, 2013, e764.
75. [75] Chu, X.Y., Chen, L.B., Wang, J.H., Su, Q.S., Yang, J.R., Lin, Y., Xue, L.J., Liu, X.B., Mo, X.B., Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J. Surg. Oncol. 105:6 (2012), 520–528.
76. [76] Tai, C.J., Chin-Sheng, H., Kuo, L.J., Wei, P.L., Lu, H.H., Chen, H.A., Liu, T.Z., Liu, J.J., Liu, D.Z., Ho, Y.S., Wu, C.H., Chang, Y.J., Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann. Surg. Oncol. 19:1 (2012), 336–343.
77. [77] Knight, B.B., Oprea-Ilies, G.M., Nagalingam, A., Yang, L., Cohen, C., Saxena, N.K., Sharma, D., Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr. Relat. Cancer 18:4 (2011), 413–428.
78. [78] Andrews, P., Thyssen, J., Lorke, D., The biology and toxicology of molluscicides, bayluscide. Pharmacol. Ther. 19:2 (1982), 245–295.
79. [79] Bruno, R.D., Vasaitis, T.S., Gediya, L.K., Purushottamachar, P., Godbole, A.M., Ates-Alagoz, Z., Brodie, A.M., Njar, V.C., Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 76:12 (2011), 1268–1279.
80. [80] Handratta, V.D., Vasaitis, T.S., Njar, V.C., Gediya, L.K., Kataria, R., Chopra, P., Newman, D. Jr., Farquhar, R., Guo, Z., Qiu, Y., Brodie, A.M., Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48:8 (2005), 2972–2984.
81. [81] Yu, Z., Cai, C., Gao, S., Simon, N.I., Shen, H.C., Balk, S.P., Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin. Cancer Res. 20:15 (2014), 4075–4085.
82. [82] Kwegyir-Afful, A.K., Ramalingam, S., Purushottamachar, P., Ramamurthy, V.P., Njar, V.C., Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget 6:29 (2015), 27440–27460.
83. [83] Njar, V.C., Brodie, A.M., Discovery and development of galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem. 58:5 (2015), 2077–2087.
84. [84] Clegg, N.J., Wongvipat, J., Joseph, J.D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E.D., Cai, L., Aparicio, A., Dorow, S., Arora, V., Shao, G., Qian, J., Zhao, H., Yang, G., Cao, C., Sensintaffar, J., Wasielewska, T., Herbert, M.R., Bonnefous, C., Darimont, B., Scher, H.I., Smith-Jones, P., Klang, M., Smith, N.D., De Stanchina, E., Wu, N., Ouerfelli, O., Rix, P.J., Heyman, R.A., Jung, M.E., Sawyers, C.L., Hager, J.H., ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72:6 (2012), 1494–1503.
85. [85] Bambury, R.M., Rathkopf, D.E., Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide. Urol. Oncol. 34:8 (2015), 348–355.
86. [86] Rathkopf, D., Liu, G., Carducci, M.A., Eisenberger, M.A., Anand, A., Morris, M.J., Slovin, S.F., Sasaki, Y., Takahashi, S., Ozono, S., Fung, N.K., Cheng, S., Gan, J., Gottardis, M., Obermeier, M.T., Reddy, J., Zhang, S., Vakkalagadda, B.J., Alland, L., Wilding, G., Scher, H.I., Prostate Cancer Clinical Trials, C., Phase, I., dose-escalation study of the novel antiandrogen: BMS-641988 in patients with castration-resistant prostate cancer. Clin. Cancer Res. 17:4 (2011), 880–887.
87. [87] Moilanen, A.M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykanen, P.S., Tormakangas, O.P., Palvimo, J.J., Kallio, P.J., Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep., 5, 2015, 12007.
88. [88] Fizazi, K., Massard, C., Bono, P., Jones, R., Kataja, V., James, N., Garcia, J.A., Protheroe, A., Tammela, T.L., Elliott, T., Mattila, L., Aspegren, J., Vuorela, A., Langmuir, P., Mustonen, M., group As, Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 15:9 (2014), 975–985.
89. [89] Andersen, R.J., Mawji, N.R., Wang, J., Wang, G., Haile, S., Myung, J.K., Watt, K., Tam, T., Yang, Y.C., Banuelos, C.A., Williams, D.E., McEwan, I.J., Wang, Y., Sadar, M.D., Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:6 (2010), 535–546.
90. [90] Martin, S.K., Banuelos, C.A., Sadar, M.D., Kyprianou, N., N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol. Oncol. 9:3 (2014), 628–639.
91. [91] Meimetis, L.G., Williams, D.E., Mawji, N.R., Banuelos, C.A., Lal, A.A., Park, J.J., Tien, A.H., Fernandez, J.G., de Voogd, N.J., Sadar, M.D., Andersen, R.J., Niphatenones, glycerol ethers from the sponge niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J. Med. Chem. 55:1 (2012), 503–514.
92. [92] Banuelos, C.A., Lal, A., Tien, A.H., Shah, N., Yang, Y.C., Mawji, N.R., Meimetis, L.G., Park, J., Kunzhong, J., Andersen, R.J., Sadar, M.D., Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One, 9(9), 2014, e107991.
93. [93] Hu, R., Isaacs, W.B., Luo, J., A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71:15 (2011), 1656–1667.